Constellation Pharmaceuticals to Participate in Two Investor Conferences

CAMBRIDGE,Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in two upcoming virtual investor conferences. Jigar Raythatha, CEO, will present at:

• The Bank of America Merrill Lynch Global Health Care Conference at 9:00 AM EDT on May 12

• The RBC Capital Markets Global Healthcare Virtual Conference at 10:55 AM EDT on May 20 

Live audio webcasts of Mr. Raythatha’s presentation and archives for replay will be available on the Investor Relations section of Constellation’s website at http://ir.constellationpharma.com/events-and-presentations/events. The audio webcast replay will be available for 90 days following the live presentation.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the EZH2 inhibitors CPI-1205 and CPI-0209 for the treatment of metastatic castration-resistant prostate cancer and other cancers as well as the BET inhibitor CPI-0610 for the treatment of myelofibrosis. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.    

Contact

Kia Khaleghpour, Ph.D.
Vice President, Investor Relations and Communications
Constellation Pharmaceuticals
+1 617-844-6859
[email protected]

Ronald Aldridge
Investor Relations
Constellation Pharmaceuticals
+1 617-714-0539
[email protected]

Lauren Arnold
Media Relations
MacDougall Biomedical Communications
+1 781-235-3060
[email protected]

You May Also Be Interested In

• With a Royal Vision and a Global Mission, the King Hamad Award for Coexistence and Tolerance is Launched, with Nominations Open Worldwide for Its Inaugural Edition
• BofA Securities Upgrades Americold Realty Trust (COLD) to Neutral
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown